ResMed Inc. (RMD) Valuation
Historical valuation analysis based on 1279 data points (2021-09-14 to 2026-10-16)
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diag...
ResMed Inc. (RMD) currently trades at a P/E ratio of 22.69 (historical range: 17.61–93.62, median: 36.77), placing it at the 11th percentile — cheap relative to its history, P/S ratio of 6.22 (range: 4.54–13.85, 24th percentile — below its historical average), EV/EBITDA of 17.87 (range: 13.61–48.76, 11th percentile).
Over the historical period (2021-09-14 to 2026-10-16), ResMed Inc.'s P/E ratio has contracted by 32% over the observed period (from an average of 44.2 to 30.1).
ResMed Inc. trades well below its historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 22.69 | 36.77 | 11th | cheap relative to its history |
| P/S Ratio | 6.22 | 7.95 | 24th | below its historical average |
| EV/EBITDA | 17.87 | 29.60 | 11th | cheap relative to its history |
| FCF Yield | 5.09% | 1.75% | 88th | cheap relative to its history |
ResMed Inc. (RMD) Valuation & P/E History
ResMed Inc. (RMD) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry currently trading at $238.97 with a market capitalization of $33.6 billion. This page provides historical valuation analysis for RMD based on 1279 data points covering 2021-09-14 to 2026-10-16. The P/E ratio of 22.69 is below the historical median of 36.77, placing RMD at the 11th percentile of its valuation range. The P/S ratio of 6.22 compares to a median of 7.95.
RMD Valuation Metrics & Historical Range
The valuation table above shows ResMed Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether RMD is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests RMD is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for ResMed Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is RMD Overvalued or Undervalued?
ResMed Inc. trades well below its historical valuation range across most metrics. The overall valuation percentile of 15 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive RMD is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full RMD analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.RMD trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.